Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul, Korea.
Gut Liver. 2024 Sep 15;18(5):824-833. doi: 10.5009/gnl230541. Epub 2024 May 10.
BACKGROUND/AIMS: The incidence of acute gastrointestinal bleeding (GIB) increases with the utilization of anticoagulant and nonsteroidal anti-inflammatory drugs (NSAIDs). This study aimed to compare the risk of GIB between anticoagulant and NSAIDs combotherapy and anticoagulant monotherapy in real-world practice.
We investigated the relative risk of GIB in individuals newly prescribed anticoagulant and NSAIDs combination therapy and that in individuals newly prescribed anticoagulant monotherapy at three hospitals using "common data model." Cox proportional hazard models and Kaplan-Meier estimation were employed for risk comparison after propensity score matching.
A comprehensive analysis of 2,951 matched pairs showed that patients who received anticoagulant and NSAIDs combousers exhibited a significantly higher risk of GIB than those who received anticoagulant monousers (hazard ratio [HR], 1.66; 95% confidence interval [CI], 1.30 to 2.12; p<0.001). The risk of GIB associated with anticoagulant and NSAIDs combination therapy was also significantly higher than that associated with anticoagulant monotherapy in patients aged >65 years (HR, 1.53; 95% CI, 1.15 to 2.03; p=0.003) and >75 years (HR, 1.89; 95% CI, 1.23 to 2.90; p=0.003). We also found that the risk of GIB was significantly higher in the patients who received anticoagulant and NSAIDs combousers than that in patients who received anticoagulant monousers in both male (p=0.016) and female cohorts (p=0.010).
The risk of GIB is significantly higher in patients who receive anticoagulant and NSAIDs combotherapy than that in patients who receive anticoagulant monotherapy. In addition, the risk of GIB associated with anticoagulant and NSAIDs combotherapy was much higher in individuals aged >75 years. Therefore, physicians should be more aware of pay more attention to the risk of GIB when they prescribe anticoagulant and NSAIDs.
背景/目的:抗凝剂和非甾体抗炎药(NSAIDs)的使用增加了急性胃肠道出血(GIB)的发生率。本研究旨在比较抗凝剂和 NSAIDs 联合治疗与抗凝剂单药治疗在真实世界实践中的 GIB 风险。
我们使用“通用数据模型”调查了在三家医院新处方抗凝剂和 NSAIDs 联合治疗和新处方抗凝剂单药治疗的个体中 GIB 的相对风险。在倾向评分匹配后,使用 Cox 比例风险模型和 Kaplan-Meier 估计进行风险比较。
对 2951 对匹配对的综合分析表明,接受抗凝剂和 NSAIDs 联合使用者的 GIB 风险显著高于接受抗凝剂单药使用者(风险比 [HR],1.66;95%置信区间 [CI],1.30 至 2.12;p<0.001)。在年龄 >65 岁(HR,1.53;95% CI,1.15 至 2.03;p=0.003)和 >75 岁(HR,1.89;95% CI,1.23 至 2.90;p=0.003)的患者中,抗凝剂和 NSAIDs 联合治疗相关的 GIB 风险也明显高于抗凝剂单药治疗相关的 GIB 风险。我们还发现,在男性(p=0.016)和女性队列(p=0.010)中,接受抗凝剂和 NSAIDs 联合使用者的 GIB 风险均明显高于接受抗凝剂单药使用者。
接受抗凝剂和 NSAIDs 联合治疗的患者发生 GIB 的风险明显高于接受抗凝剂单药治疗的患者。此外,在年龄 >75 岁的个体中,抗凝剂和 NSAIDs 联合治疗相关的 GIB 风险更高。因此,当医生开具抗凝剂和 NSAIDs 时,应更加注意 GIB 的风险。